MetaCap

Alterity Therapeutics (ATHE) vs Rein Therapeutics (RNTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alterity Therapeutics (ATHE) has outperformed Rein Therapeutics (RNTX) over the past year, losing 56.7% versus a loss of 77.2%. Over five years, ATHE leads with a -85.4% price change compared with -97.5% for RNTX. Rein Therapeutics is the larger company by market cap ($29.1 million vs $29.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATHE-56.70%RNTX-77.24%
+75%-5%-84%
Nov 21, 20251 yearNov 20, 2026
ATHE-85.93%RNTX-97.57%
+5%-49%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATHE versus RNTX key metrics
MetricATHERNTX
Share price$1.52$0.3369
Market cap$29.02M$29.06M
1-day change-8.16%-8.38%
YTD return-50.65%-70.96%
1-year return-56.70%-77.24%
5-year return-85.38%-97.47%
EPS (TTM)$-0.90$-1.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)—$-49.87M
52-week high$5.89$2.10
52-week low$1.52$0.284
Distance from 52-week high-74.19%-83.96%
Analyst consensusnonenone
Avg. price target upside+771.71%+1680.94%
Average volume89.63K586.68K
Shares outstanding19.09M86.27M
Employees1110
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ATHE has outperformed RNTX by 20.5 percentage points over the past year.

About Alterity Therapeutics

ATHE stock →

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About Rein Therapeutics

RNTX stock →

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

ATHE vs RNTX FAQ

Which is bigger, Alterity Therapeutics or Rein Therapeutics?

Rein Therapeutics (RNTX) is larger, with a market capitalization of $29.06M compared with $29.02M for Alterity Therapeutics (ATHE).

Which stock has performed better over the past year, ATHE or RNTX?

ATHE returned -56.70% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.

Are Alterity Therapeutics and Rein Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons